Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbCellera Biologics Inc.

www.abcellera.com

Latest From AbCellera Biologics Inc.

AbCellera Finds Antibody Candidates Other Technologies Might Not

Emerging Company Profile: A platform research company, AbCellera is not developing any drugs, but has seen triple-digit revenue growth each year since 2015 via a model of discovering next-generation therapeutic antibody candidates for partners.

Platform Technologies Business Strategies

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Business Strategies Commercial

Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.

Deals Financing

Finance Watch: Government Grants Galore And Other New Funding Sources

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • AbCellera Biologics Inc.
  • Senior Management
  • Carl L Hansen, PhD, Pres. & CEO
    Erika Kinney, CPA, CA, Controller
    Murray McCutcheon, PhD, BD & Licensing
    Kevin Heyries, PhD, BD & Strategy
  • Contact Info
  • AbCellera Biologics Inc.
    Phone: (604) 827-2128
    2215 Yukon Street
    Vancouver, V5Y 0A1
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register